scispace - formally typeset
N

Nalinee Sangrujee

Researcher at Centers for Disease Control and Prevention

Publications -  18
Citations -  736

Nalinee Sangrujee is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Cost effectiveness & Population. The author has an hindex of 14, co-authored 18 publications receiving 707 citations.

Papers
More filters
Journal ArticleDOI

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: A combined analysis of 12 mathematical models

Jeffrey W. Eaton, +59 more
TL;DR: Estimates suggest that earlier eligibility for antiretroviral therapy is very cost effective in low-income and middle-income settings, although these estimates should be revisited when more data become available.
Journal ArticleDOI

Cost-Effectiveness Analysis of Diagnostic Options for Pneumocystis Pneumonia (PCP)

TL;DR: For diagnosis of PCP, use of PCR technologies, when combined with less-invasive patient specimens such as expectorated or induced sputum, represent more cost-effective options than any diagnostic procedure using BAL, or chest x-ray alone.
Journal ArticleDOI

Cost-effectiveness of three different vaccination strategies against measles in Zambian children

TL;DR: A vaccination program which includes SIAs reaching children not previously vaccinated would prevent on additional 29,242 measles cases and 1462 deaths for each vaccinated birth cohort when compared with a one-dose program.
Journal ArticleDOI

HIV Treatment as Prevention: Issues in Economic Evaluation

TL;DR: Economic evaluations of antiretroviral therapy in currently existing programs and in HIV treatment as prevention (TasP) programs should use cost functions that capture cost dependence on a number of factors, such as scale and scope of delivery.
Journal ArticleDOI

Cost analysis of post-polio certification immunization policies

TL;DR: Projections on the vaccine price per dose and future coverage rates were major drivers of the global costs of post-certification polio immunization.